# A Phase II Clinical Trial of TQC3721 Suspension for Inhalation

> **NCT05292196** · PHASE2 · TERMINATED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 59 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** TQC3721 suspension for inhalation
- **DRUG:** TQC3721 suspension placebo for inhalation

## Key facts

- **NCT ID:** NCT05292196
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-20
- **Primary completion:** 2023-01-11
- **Final completion:** 2023-12-05
- **Target enrollment:** 59 (ACTUAL)
- **Why stopped:** Per sponsor request. Closure was not prompted by any safety or efficacy concerns.
- **Last updated:** 2025-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05292196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05292196, "A Phase II Clinical Trial of TQC3721 Suspension for Inhalation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05292196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*